R&D

Pipeline

The hero of the global First-in Class is Hanmi Pharmaceutical.
Hanmi Pharmaceutical is developing about 30 innovative new drugs in the areas of anti-cancer, obesity, diabetes, rare diseases, and immunization diseases.

New Drug Development Status

Last updated 2019-11-13

BIO
Research
Area
Project Indication Preclinical Clinical Licensing
Phase 1 Phase 2 Phase 3
BIO

Rolontis(eflapegrastim)

Every three weeks administration*Spectrum code: SPI-2012

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Spectrum

Chemotherapy-
induced neutropenia

complete

complete

complete

complete

Spectrum

efpeglenatideLAPSExd4 Analog

Once weekly~monthly (GLP-1)*Sanofi code: SAR-439977

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Sanofi

Diabetes

complete

complete

complete

ongoing

Sanofi

efpegsomatropin(LAPShGH)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Growth hormone
deficiency

complete

complete

complete

uncompleted

none

HM12525A(LAPSGLP/GCG)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Diabetes, Obesity

complete

complete

ongoing

uncompleted

none

HM12460A / HM12470(LAPSInsulin / LAPSInsulin Analog)

A long-acting insulin or insulin

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Type 1 & 2 Diabetes

complete

complete

uncompleted

uncompleted

none

HM15211(LAPSTriple Agonist)

Once weekly administration (GLP/GIP/GCG)

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

NASH

complete

ongoing

uncompleted

uncompleted

none

HM15136(LAPSGlucagon Analog)

Once weekly administration (Glucagon)

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Obesity
Congenital hyperinsulinism

complete

ongoing

uncompleted

uncompleted

none

HM14220LAPSInsulin Combo

efpeglenatide +LAPSInsulin Analog

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Sanofi

Type 2 Diabetes

complete

uncompleted

uncompleted

uncompleted

Sanofi

HM15450(LAPSASB)

Once monthly administration (LSD treatment)

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Mucopolysaccharidosis

ongoing

uncompleted

uncompleted

uncompleted

none

HM15912(LAPSGLP-2 Analog)

Once weekly administration (GLP-2)

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Short bowel syndrome

complete

ongoing

uncompleted

uncompleted

none

HM21001(GBM Stem Cell Therapy)

Glioblastoma (GBM) stem cell therapy

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Ajou University

Glioblastoma

ongoing

uncompleted

uncompleted

uncompleted

Ajou University

HM14320(LAPSGlucagon Combo)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Obesity, NASH, Diabetes

ongoing

uncompleted

uncompleted

uncompleted

none

HM12480(LAPSInsulin 148)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Diabetes

ongoing

uncompleted

uncompleted

uncompleted

none

NCE
Research
area
Project Indication Preclinical Clinical Licensing
Phase 1 Phase 2 Phase 3
NCE

Oraxol(paclitaxel + encequidar)

Oral paclitaxel

encequidar: Oral absorption enhancer

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Athenex

Solid tumors
(Breast cancer)

complete

complete

complete

ongoing

Athenex

Luminate®(ALG-1001)

Integrin modulator

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Allegro

Diabetic Mascular Edema Pigmentosa

complete

complete

complete

uncompleted

Allegro

Retinitis Pigmentosa

complete

ongoing

uncompleted

uncompleted

HM71224(BTK)

Bruton's tyrosine kinase (BTK) inhibitor

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
Autoimmune
disease

complete

complete

ongoing

uncompleted

none

poziotinib(pan-HER)

pan-HER inhibitor

Multi-targeted anti-cancer drug

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Spectrum|Luye

Solid tumors
(breast, lung cancer)

complete

complete

ongoing

uncompleted

Spectrum|Luye

Oratecan(irinotecan + encequidar)

Oral irinotecan

encequidar: Oral absorption enhancer

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Athenex

Solid tumors
(Colorectal cancer)

complete

complete

ongoing

uncompleted

Athenex

Oradoxel(Docetaxel+encequidar)

Oral docetaxel

encequidar: Oral absorption enhancer

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Athenex

Solid tumors

complete

complete

ongoing

uncompleted

Athenex

belvarafenib(pan-RAF)

pan-RAF inhibitor

Multi-targeted anti-cancer drug*Genentech code: RG6185

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Genentech

Solid tumors

complete

Phase 1 ongoing

uncompleted

uncompleted

Genentech

FLT3

FMS-like tyrosine kinase 3 inhibitor

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
AML (Acute Myeloid Leukemia)

complete

Phase 1 ongoing

uncompleted

uncompleted

EZH1/2

Enhancer of zeste homolog 1/2 (EZH1/2) dual inhibitor

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Solid tumors, Hematologic cancers

ongoing

uncompleted

uncompleted

uncompleted

none

LSD1

Lysine-specific histone demethylase 1 (LSD1) inhibitor

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

SCLC (Small Cell Lung Cancer), AML (Acute Myeloid Leukemia)

ongoing

uncompleted

uncompleted

uncompleted

none

ADOR

Adenosine receptor(ADOR) antagonist

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Solid tumors

ongoing

uncompleted

uncompleted

uncompleted

none

BIO
Beijing Hanmi’s New Drug Pipeline
BIO

BH2950(PD-1/Her2 BsAb)

A bispecific antibody for targeted immuno-oncology

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Solid tumors

ongoing

uncompleted

uncompleted

uncompleted

INNOVENT

BH2996h(PD-1/PD-L1 BsAb)

A bispecific antibody for targeted immuno-oncology

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Solid tumors

ongoing

uncompleted

uncompleted

uncompleted

none

PD-L1/CD47 BsAb

A bispecific antibody for targeted immuno-oncology

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Solid tumors

ongoing

uncompleted

uncompleted

uncompleted

none

BH1657(TNF-α/IL-17 BsAb)

A bispecific antibody for targeted autoimmune diseases

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Rheumatoid
Arthritis

ongoing

uncompleted

uncompleted

uncompleted

none